Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Drug:  anti-endoglin monoclonal antibody TRC105
Find trials that include:  Any drugs shown
Results 1-8 of 8 for your search:
Start Over
A RANDOMIZED PHASE 3 TRIAL OF TRC105 AND PAZOPANIB VERSUS PAZOPANIB ALONE IN PATIENTS WITH ADVANCED ANGIOSARCOMA
Status: Active
Phase: Phase III
Type: Treatment
Age: 12 and over
Trial IDs: 105SAR301, NCI-2017-00569, NCT02979899
A Randomized Phase 2 Trial of Axitinib and TRC105 Versus Axitinib Alone in Patients With Advanced or Metastatic Renal Cell Carcinoma
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 105RC101, NCI-2013-01264, NCT01806064
A Phase 1B Dose-escalation and Phase 2a Study of TRC105 in Combination With Pazopanib in Patients With Advanced Soft Tissue Sarcoma
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 105SAR101, NCI-2014-00305, NCT01975519
An Open Label Continuation Study of TRC105 Therapy for Patients Who Have Completed a Prior TRC105 Trial and Are Judged by the Investigator to Have the Potential to Benefit From Continued TRC105 Therapy
Status: Enrolling by invitation
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 105CON101, NCI-2013-00735, NCT02354612
Trial of TRC105 and Sorafenib in Patients With HCC
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 105HCC101, NCI-2016-00131, NCT02560779
Study of TRC105 and Bevacizumab in Patients With Refractory Gestational Trophoblastic Neoplasia (GTN)
Status: Active
Phase: Phase II
Type: Treatment
Age: 16 to 99
Trial IDs: 105GTN201, NCI-2017-00335, NCT02664961
Anti-endoglin Chimeric Monoclonal Antibody TRC105 with Paclitaxel, Carboplatin, and Bevacizumab in Treating Patients with Stage IV Lung Cancer
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 19 and over
Trial IDs: UAB1504, NCI-2015-01379, F150128005, IRB00000726, 105LC101, NCT02429843
Start Over